HUA MEDICINE (SHANGHAI) LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.62 HKD | +1.89% |
|
+8.00% | -17.77% |
| Mar. 28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
Presenter SpeechZiyi Chen (Analysts)Before we kick up the session, I would like to highlight t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.5
CNY
Average target price
3.072
CNY
Spread / Average Target
+104.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.77% | 203M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2552 Stock
- News Hua Medicine (Shanghai) Ltd.
- Transcript : Hua Medicine Ltd., 2022 Earnings Call, Mar 30, 2023
